UnitedHealth and Anthem get whacked as their multiples get out of whack with historic levels.
Shares are moving down on news; thus, closing on that news makes trader-sense.
Charts show DGX should break out above resistance soon.
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.

Gilead Leads a Biotech Rally Real Money Pro($)

The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
Becoming the influential firm's number one holding is a decisive vote of confidence.
Above $156 would be a place to get aggressive.
These two will continue to churn out earnings growth.
New examples of price-gouging emerge from Mallinckrodt Pharmaceuticals.
For upside, there is clear resistance at $110.

Columnist Conversations

We continue to be upbeat about select healthcare for the upcoming 3 to 12 months. We like select Biotech/Pharm...
Market continues to be slightly down at midday. Biotech taking a big hit today with the major indices down mo...
If I'm reading the argument correctly, because other governments want to take their taxpayers' money and redir...
MF approves adding Chinese yuan to SDR basket. Inclusion is effective 1-Oct-2016.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.